Recurrent Gastrointestinal Carcinoid Tumor Completed Phase 2 Trials for Bevacizumab (DB00112)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0028801 (Recurrent Gastrointestinal Carcinoid Tumor) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00055809 | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | Treatment |